☆ 4.6 Article

CAR T cell-driven cerebrospinal fluid cytokine storm with confounding neurological picture in chemorefractory primary cardiac lymphoma

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network

Marion Alcantara et al.

BLOOD (2022)

Add to Collection

Article Oncology

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Lihua E. Budde et al.

Summary: This study evaluated the safety, tolerability, and efficacy of mosunetuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs). The results showed that mosunetuzumab has a manageable safety profile and induces durable complete responses in some patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

Marc Wehrli et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy, while effective in treating tumors, is associated with acute toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Current treatment guidelines for CRS and ICANS recommend the use of tocilizumab and corticosteroids. This study retrospectively analyzed the use of anakinra, a drug that blocks the interleukin-1 receptor, in managing steroid-refractory ICANS. The use of anakinra resulted in significant reduction in fever and inflammatory cytokines, but did not have a dramatic effect on neurotoxicity or the tapering of corticosteroids.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Hematology

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: survival update and new extension cohort data

Laurie H. Sehn et al.

Summary: Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on the results of the GO29365 study. The study reported updated results from the randomized arms and the extension cohort, showing that pola + BR is an effective treatment option with a well-characterized safety profile.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Matthew J. Frigault et al.

Summary: This study conducted a clinical trial of tisagenlecleucel in highly refractory patients with primary central nervous system lymphoma (PCNSL). The results showed that most patients responded well to the treatment and there were no severe side effects. This suggests that tisagenlecleucel is safe and effective in this patient population.

BLOOD (2022)

Add to Collection

Article Oncology

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

Grzegorz S. Nowakowski et al.

Summary: In this retrospective study, the combination of tafasitamab and lenalidomide showed a significant improvement in overall survival compared to other treatment regimens for relapsed/refractory diffuse large B-cell lymphoma.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma (Publication with Expression of Concern. See vol. 4, pg. 246, 2023)

Neeraj Y. Saini et al.

Summary: This study reveals that clonal hematopoiesis mutations, particularly those associated with inflammation (DNMT3A, TET2, and ASXL1), are associated with severe-grade neurotoxicities in lymphoma patients receiving anti-CD19 CAR T-cell therapy. Furthermore, the incidence of therapy-related myeloid neoplasms after CAR T-cell therapy is higher in clonal hematopoiesis-positive patients.

BLOOD CANCER DISCOVERY (2022)

Add to Collection

Review Immunology

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Emma C. Morris et al.

Summary: CAR T cell therapy has revolutionized the field of cancer treatment, but significant toxicities can occur in up to one-third of patients. The most common toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Understanding their pathophysiology is crucial for developing novel therapeutics for prevention and management.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection

Article Hematology

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Vicki Plaks et al.

BLOOD (2021)

Add to Collection

Article Hematology

CD19 directed CAR T cell therapy for treatment of primary CNS lymphoma

Tanya Siddiqi et al.

Blood Advances (2021)

Add to Collection

Article Oncology

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019

Haoguang Chen et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Oncology

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma

Christopher M. Wright et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Add to Collection

Article Oncology

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

Kevin R. Parker et al.

CELL (2020)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

Add to Collection

Article Clinical Neurology

Neurological toxicities associated with chimeric antigen receptor T-cell therapy

Daniel B. Rubin et al.

BRAIN (2019)

Add to Collection

Article Oncology

CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions

Bradley D. Hunter et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Add to Collection

Article Pharmacology & Pharmacy

Polatuzumab Vedotin: First Global Approval

Emma D. Deeks

DRUGS (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Hematology

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Michael R. Bishop et al.

BLOOD ADVANCES (2019)

Add to Collection

Article Medicine, General & Internal

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures

Veerle A. B. van den Bogaard et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Jeannette Fischer et al.

JOURNAL OF IMMUNOTHERAPY (2017)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Biology

Pathology and biology of radiation-induced cardiac disease

Soile Tapio

JOURNAL OF RADIATION RESEARCH (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.